| Name | Title | Contact Details |
|---|---|---|
Alexandre Ledoux |
Director, Research and Development | Profile |
Novel therapeutics for metabolic and endocrine disorders
Welcome to GenRx Pharmacy in Scottsdale, AZ. Visit our website for our location, information and new patient sign ups.
Learn how Eko brings together stethoscopes, patient & provider software, and AI-powered analysis—elevating the way we detect and monitor cardiovascular disease.
Ocularis Pharma, Inc. is a Riverside, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.